Live Cell Encapsulation Market to Reach USD 303 million by 2024

[Divya Dsouza]

This report aims to provide detailed insights into the global live cell encapsulation market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

Key Factors Driving Market Growth:

The major factors driving the growth of the Live Cell Encapsulation Industry are the rising public awareness related to the clinical role of encapsulated cells in disease management, increasing public-private investments to support product development, and the rising adoption of novel drug delivery systems for disease treatment.

Revenue Growth Analysis:

The global Cell Encapsulation Industry is projected to reach USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2%.

Don't miss out on business opportunities in Live Cell Encapsulation Market

Simple dripping segment is expected to account for the largest share of the Live Cell Encapsulation Market, by manufacturing technique, in 2018

Based on manufacturing technique, the Live Cell Encapsulation Industry is segmented into . The instruments segment is expected to account for the largest share of the Live Cell Encapsulation Industry in 2019. The increasing adoption due to the procedural benefits (such as simple process, product biocompatibility, and low particle size distribution) are the major factors driving the growth of this market segment.

Browse in-depth TOC on "Live Cell Encapsulation Market"

64 – Tables
31 – Figures
138 – Pages

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218019375

Alginate polymers segment estimated to be the fastest-growing polymer type segment during the forecast period

Based on polymer type, the Live Cell Encapsulation Industry is segmented into alginate, HEMA-MMA (hydroxyethyl methacrylate-methyl methacrylate), chitosan, siliceous encapsulates, cellulose sulfate, PAN-PVC [poly (acrylonitrile vinyl chloride)], and other polymers. The alginate segment is expected to grow at the highest CAGR during the forecast period primarily due to the procedural benefits such as uniform cell structures and high mechanical stability.

Drug delivery to account for the largest share of the Live Cell Encapsulation Market, by application, in 2018

Based on end user, the Live Cell Encapsulation Industry is segmented into drug delivery, regenerative medicine, cell transplantation, probiotics, and research. Drug delivery are estimated to be the largest application of live cell encapsulation, and this trend is expected to continue during the forecast period. The large share of this application segment can be attributed to the ongoing technological advancements in the field of cell encapsulation and increased product affordability, and usage of biocompatible immobilization or isolation systems.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=218019375

North America to dominate the Live Cell Encapsulation Market during the forecast period

The Live Cell Encapsulation Industry is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is estimated to be the largest regional market for live cell encapsulation in 2019 majorly due to the increasing clinical data for the efficacy of the cell encapsulation technique and the rising adoption of cell encapsulation techniques among medical professionals.

Key Players:

The major players operating in the Live Cell Encapsulation Industry are BioTime, Inc. (US), Reed Pacific Pty Ltd. (Australia), Viacyte, Inc. (US), Neurotech Pharmaceuticals, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top five players in the global Live Cell Encapsulation Industry. Other prominent players operating in this market include Merck KGAA (Germany), Sigilon Therapeutics, Inc. (US), Encapsys, LLC (US), Evonik Industries (Germany), Lycored (Israel), MiKroCaps (Slovenia), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), Sernova Corporation (Canada), and Balchem Corporation (US), among others.